HUMANIGEN
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
HUMANIGEN
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2001-01-01
Address:
Burlingame, California, United States
Country:
United States
Website Url:
http://www.humanigen.com
Total Employee:
1+
Status:
Active
Contact:
650-243-3100
Email Addresses:
[email protected]
Total Funding:
369.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Euro
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Verastem Oncology
Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Humanigen
Cheval Holdings
Cheval Holdings investment in Post-IPO Equity - Humanigen
Nomis Bay
Nomis Bay investment in Post-IPO Equity - Humanigen
Black Horse Capital Advisors
Black Horse Capital Advisors investment in Post-IPO Equity - Humanigen
Fidelity
Fidelity investment in Private Equity Round - Humanigen
Alloy Ventures
Alloy Ventures investment in Series D - Humanigen
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series D - Humanigen
Sofinnova Investments
Sofinnova Investments investment in Series D - Humanigen
5AM Ventures
5AM Ventures investment in Series D - Humanigen
GBS Ventures
GBS Ventures investment in Series D - Humanigen
Key Employee Changes
| Date | New article |
|---|---|
| 2021-06-07 | Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations |
Official Site Inspections
http://www.humanigen.com Semrush global rank: 1.13 M Semrush visits lastest month: 28.57 K
Unable to get host informations!!!
More informations about "Humanigen"
humanigen.com
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for cancer and immune disorders using cutting-edge antibody technologies.See details»
Humanigen, Inc. - LinkedIn
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating …See details»
Humanigen - Crunchbase Company Profile & Funding
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics.See details»
Humanigen 2025 Company Profile: Valuation, Investors …
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to …See details»
Humanigen, Inc. Information - RocketReach
Humanigen, Inc. is a Pharmaceutical Manufacturing, Hospitals & Clinics, and Biotechnology company located in Short Hills, New Jersey with $324000 in revenue and 7 employees. Find …See details»
Humanigen - 2025 Company Profile, Funding & Competitors
Jun 10, 2025 Humanigen is a public company based in Brisbane (United States), founded in 2000. It operates as a Developer of small molecules and monoclonal antibodies for rare …See details»
Humanigen, Inc.: Shareholders Board Members Managers and …
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno …See details»
Humanigen - Products, Competitors, Financials, Employees, …
Humanigen is a clinical-stage biopharmaceutical company focused on the treatment of cancers and infectious diseases, including COVID-19. Use the CB Insights Platform to explore …See details»
Humanigen Company Profile - Office Locations, Competitors
Jul 18, 2024 Humanigen has 5 employees across 4 locations and $2.51 m in annual revenue in FY 2022. See insights on Humanigen including office locations, competitors, revenue, …See details»
Humanigen is a biopharmaceutical company that focuses on …
Description: Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It …See details»
Humanigen, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jun 15, 2025 Explore Humanigen, Inc. with its drug pipeline, therapeutic area, technology platform, 10 clinical trials, 80 news, and 8 literature, Disease Domain:Neoplasms, Hemic and …See details»
Humanigen | F6S
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating …See details»
Humanigen Corporate Overview & Mission Statement February 2022
February 17, 202208:00 PM Add to Calendar Add to Apple Calendar Add to Google Calendar Add to Microsoft Outlook Add to iCalendar View PresentationPDF2.42 MBSee details»
Humanigen facing bankruptcy as reverse merger fails
2 days ago Three years ago, Humanigen was riding high with a COVID-19 therapy in late-stage testing and shares worth upwards of $20 apiece. Now, it is facing the threat of bankruptcy and …See details»
Humanigen Inc. - Humanigen Adds to Board of Directors
Burlingame, CA, December 16, 2019 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other …See details»
Humanigen Announces Participation and Presentation at Multiple ...
Jun 3, 2022 Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response …See details»
Humanigen Inc. - Timothy Morris Joins Humanigen as Chief …
Burlingame, CA, August 3, 2020 – Humanigen, Inc. , (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome …See details»
Humanigen Elects Dr. Dale Chappell to Board of Directors
Feb 8, 2021 Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response …See details»
Humanigen to Present at BIO CEO & Investor Conference
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today …See details»
Humanigen Reports Year-End 2021 Financial Results
Feb 28, 2022 Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response …See details»